Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:
  • Recruiting  
  • « Prev · Page 11

NCT ID: NCT01303887 Recruiting - Follicular Lymphoma Clinical Trials

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

PACIFICO
Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether R-FC is more beneficial that R-CVP in the treatment of older patients (aged 60 or over) with Follicular Lymphoma (FL).

NCT ID: NCT01151358 Recruiting - Follicular Lymphoma Clinical Trials

Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy

MERIT-NHL
Start date: May 2008
Phase: N/A
Study type: Observational

MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive. Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.

NCT ID: NCT00722930 Recruiting - Follicular Lymphoma Clinical Trials

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma

GOTEL-FL1LC
Start date: April 2008
Phase: Phase 2
Study type: Interventional

To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy

NCT ID: NCT00530140 Recruiting - Follicular Lymphoma Clinical Trials

Idiotypic Vaccination for Follicular Lymphoma Patients

FLIDVAX2006
Start date: October 2007
Phase: Phase 2
Study type: Interventional

Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve second (first, in the case of patients who have never achieved complete response following standard first-line treatment) complete response through autologous stem cell transplant prior to vaccination start. The ultimate goal is a cure, defined as a vaccine-maintained complete response lasting both at least 10 years and at least twice as long as each patient's first complete response.

NCT ID: NCT00455416 Recruiting - Follicular Lymphoma Clinical Trials

Dietary Intervention in Follicular Lymphoma

KLYMF
Start date: April 2007
Phase: Phase 2
Study type: Interventional

A dietary intervention study in patients with Follicular Lymphoma (FL) Stage III/IV to assess the ability of several dietary factors to induce apoptosis, inhibit cell proliferation and modulate tumor cell infiltrate in vivo.